Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Peginterferon alfa-2a in patients with chronic hepatitis C

Article Abstract:

Peginterferon alpha-2a is more effective than interferon alpha-2a in treating hepatitis C and can be taken once a week rather than three times a week. Peginterferon alpha-2a is a form of interferon alpha-2a that is easier to absorb and stays in the body for longer periods of time.

Author: Zeuzem, Stefan, Feinman, S. Victor, Rasenack, Jens, Heathcote, E. Jenny, Lai, Ming-Yang, Gane, Edward, O'Grady, John, Reichen, Jurg, Diago, Moises, Lin, Amy, Hoffman, Joseph, Brunda, Michael J.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2000

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

Article Abstract:

Peginterferon alpha-2a is more effective than interferon alpha-2a in treating hepatitis C infection, according to a study of 271 patients. Peginterferon alpha-2a is a form of interferon alpha-2a that is easier to absorb and stays in the body for longer periods of time. For this reason, it can be taken once a week rather than three times a week.

Author: Heathcote, E. Jenny, Lin, Amy, Hoffman, Joseph, Shiffman, Mitchell L., Cooksley, W. Graham E., Dusheiko, Geoffrey M., Lee, Samuel S., Balart, Luis, Reindollar, Robert, Reddy, Rajender K., Wright, Teresa L., De Pamphilis, Jean
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2000

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Telbivudine versus lamivudine in patients with chronic hepatitis B

Article Abstract:

Patients with chronic hepatitis B are randomly assigned to receive some amount of telbivudine or lamivudine once daily and the primary efficacy end point is noninferiority of telbivudine to lamivudine for therapeutic response. Telbivudine demonstrated greater HBV DNA suppression with less resistance than did lamivudine in both the HBeAg-negative and the HBeAg-positive groups of patients.

Author: Zeuzem, Stefan, Rasenack, Jens, Gane, Edward, Goodman, Zachary, Heathcote, Jenny, Yun-Fan Liaw, Thongsawat, Satawat, Ching-Lung Lui, Chao-Wei Hsu, Yuming Wang, Yagang Chen, Constance, Barbara Fielman, Bzowej, Natalie, Naoumov, Nikolai V., xDi Bisceglie, Adrian M., Brown, Nathaniel A., Young Myoung Moon, Chao, George
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2007
United States, Science & research, Research, Dosage and administration, Hepatitis B, Lamivudine, Clinical report

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Health aspects, Drug therapy, Hepatitis C, Interferon alpha
Similar abstracts:
  • Abstracts: Liver disease in patients with hereditary hemorrhagic telangiectasia. Infliximab maintenance therapy for fistulizing Crohn's disease
  • Abstracts: The risk of stomach cancer in patients with gastric or duodenal ulcer disease. Obesity, hypertension, and the risk of kidney cancer in men
  • Abstracts: Scientists probe aldosterone's role in hypertension and heart disease. Panel Predicts Shortfall in Care for the Aged
  • Abstracts: Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States
  • Abstracts: Increasing proportion of late diagnosis of HIV infection among patients with AIDS in Italy following introduction of combination antiretroviral therapy
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.